Trial Profile
A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Phase 2/3 Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With Persistent Corneal Epithelial Defects (NEXPEDE-1)
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Lufepirsen (Primary)
- Indications Corneal injuries
- Focus Therapeutic Use
- Acronyms NEXPEDE-1
- Sponsors Amber Ophthalmics
- 21 Jul 2023 Status changed from planning to recruiting.
- 09 Oct 2018 New trial record
- 02 Oct 2018 According to an Eyevance Pharmaceuticals media release, the company expects to initiate this trial in Q1 2019.